IDH1 and central nervous system cancer: Although patients with IDH1 mutations are generally younger, a multivariate analysis has confirmed that IDH1 mutation can be considered a favorable independent prognostic marker in Grade III and IV gliomas, but not in WHO Grade II astrocytomas (22, 23).